These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 34180041)

  • 1. Using Emoji Stickers to Understand End-User Opinions of the Dapivirine Vaginal Ring for HIV Prevention.
    Katz AWK; Mansoor LE; Tsidya M; Mathebula F; Singh D; Siva S; Akello C; Chitowa TH; Garcia M; Soto-Torres L; Montgomery ET
    AIDS Behav; 2021 Dec; 25(12):3955-3966. PubMed ID: 34180041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study.
    Baeten JM; Palanee-Phillips T; Mgodi NM; Mayo AJ; Szydlo DW; Ramjee G; Gati Mirembe B; Mhlanga F; Hunidzarira P; Mansoor LE; Siva S; Govender V; Makanani B; Naidoo L; Singh N; Nair G; Chinula L; Parikh UM; Mellors JW; Balán IC; Ngure K; van der Straten A; Scheckter R; Garcia M; Peda M; Patterson K; Livant E; Bunge K; Singh D; Jacobson C; Jiao Y; Hendrix CW; Chirenje ZM; Nakabiito C; Taha TE; Jones J; Torjesen K; Nel A; Rosenberg Z; Soto-Torres LE; Hillier SL; Brown ER;
    Lancet HIV; 2021 Feb; 8(2):e87-e95. PubMed ID: 33539762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Male Partner Opinions of the Dapivirine Vaginal Ring Used During an Open-Label Extension HIV Prevention Trial in KwaZulu-Natal, South Africa.
    Morar NS; Mansoor LE; Naidoo K; Katz AWK; Garcia M; Duma C; Precious Myeni NB; Tshbalala T; Naidoo S; Montgomery ET
    J Acquir Immune Defic Syndr; 2023 Feb; 92(2):127-133. PubMed ID: 36302179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does the Ring Work? Perceptions and Understanding of the Efficacy of a Dapivirine Vaginal Ring for HIV Prevention Amongst Women in a Placebo-Controlled Trial.
    Etima J; Katz AWK; Duby Z; Garcia M; Palanee-Phillips T; Reddy K; Mathebula F; Zimba C; Mansoor LE; Singh D; Manengamambo E; Naidoo S; Soto-Torres L; Montgomery ET;
    AIDS Behav; 2022 May; 26(5):1597-1606. PubMed ID: 34727272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Women's Home Environment on Use of the Dapivirine Vaginal Ring for HIV Prevention in Sub-Saharan Africa.
    Gichane MW; Katz AWK; Ngure K; Scheckter R; Woeber K; Reddy K; Tauya T; Zimba C; Etima J; Mangxilana N; Palanee-Phillips T; van der Straten A;
    AIDS Behav; 2021 Dec; 25(12):3847-3857. PubMed ID: 34009480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ring-ing in the Future: Participant and Male Partner Perspectives Regarding Future Use of the Dapivirine Vaginal Ring for HIV Prevention.
    Reddy K; Mathebula F; Katz A; Luecke E; Tenza S; Palanee-Phillips T; Garcia M; Mansoor LE; Naidoo S; Morar N; Chitukuta M; Tsidya M; Montgomery ET;
    AIDS Behav; 2022 Jun; 26(6):1923-1932. PubMed ID: 35064389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, Acceptability and Adherence of Dapivirine Vaginal Ring in a Microbicide Clinical Trial Conducted in Multiple Countries in Sub-Saharan Africa.
    Nel A; Bekker LG; Bukusi E; Hellstrӧm E; Kotze P; Louw C; Martinson F; Masenga G; Montgomery E; Ndaba N; van der Straten A; van Niekerk N; Woodsong C
    PLoS One; 2016; 11(3):e0147743. PubMed ID: 26963505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study.
    Nel A; van Niekerk N; Van Baelen B; Malherbe M; Mans W; Carter A; Steytler J; van der Ryst E; Craig C; Louw C; Gwetu T; Mabude Z; Kotze P; Moraba R; Tempelman H; Gill K; Kusemererwa S; Bekker LG; Devlin B; Rosenberg Z;
    Lancet HIV; 2021 Feb; 8(2):e77-e86. PubMed ID: 33539761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention and Association with Adherence in a Phase III Trial.
    Mayo AJ; Browne EN; Montgomery ET; Torjesen K; Palanee-Phillips T; Jeenarain N; Seyama L; Woeber K; Harkoo I; Reddy K; Tembo T; Mutero P; Tauya T; Chitukuta M; Gati Mirembe B; Soto-Torres L; Brown ER; Baeten JM; van der Straten A;
    AIDS Behav; 2021 Aug; 25(8):2430-2440. PubMed ID: 33713213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Women's motivations for participating in the dapivirine vaginal ring open label extension study.
    Naidoo K; Montgomery ET; Katz AWK; Garcia M; Naidoo S; Mansoor LE
    AIDS Care; 2024 Mar; 36(3):326-342. PubMed ID: 37734338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and Virologic Outcomes Following Initiation of Antiretroviral Therapy Among Seroconverters in the Microbicide Trials Network-020 Phase III Trial of the Dapivirine Vaginal Ring.
    Riddler SA; Balkus JE; Parikh UM; Mellors JW; Akello C; Dadabhai S; Mhlanga F; Ramjee G; Mayo AJ; Livant E; Heaps AL; O'Rourke C; Baeten JM;
    Clin Infect Dis; 2019 Jul; 69(3):523-529. PubMed ID: 30346511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Influence of Perceived Dapivirine Vaginal Ring Effectiveness on Social Disclosure and Ring Adherence.
    Stoner MCD; Brown ER; Palanee-Phillips T; Mansoor LE; Tembo T; Nair G; Akello C; Seyama L; Jeenarain N; Naidoo L; Mgodi N; Hunidzarira P; Chitukuta M; van der Straten A;
    AIDS Behav; 2021 Dec; 25(12):4169-4179. PubMed ID: 33939034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Power of the Shared Experience: MTN-020/ASPIRE Trial Participants' Descriptions of Peer Influence on Acceptability of and Adherence to the Dapivirine Vaginal Ring for HIV Prevention.
    Katz AWK; Naidoo K; Reddy K; Chitukuta M; Nabukeera J; Siva S; Zimba C; Montgomery ET
    AIDS Behav; 2020 Aug; 24(8):2387-2399. PubMed ID: 31980993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlates of Adherence to the Dapivirine Vaginal Ring for HIV-1 Prevention.
    Husnik MJ; Brown ER; Dadabhai SS; Gaffoor Z; Jeenarain N; Kiweewa FM; Livant E; Mansoor LE; Mirembe BG; Palanee-Phillips T; Singh D; Siva S; Soto-Torres L; van der Straten A; Baeten JM;
    AIDS Behav; 2021 Sep; 25(9):2801-2814. PubMed ID: 34117592
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Action of the Dapivirine Vaginal Ring as Understood by Women Participating in an Open Label Extension Study.
    Naidoo K; T ME; Katz AW; Morgan G; Krishnaveni R; Lydia ST; Sarita N; Leila ME
    AIDS Behav; 2023 Jan; 27(1):75-81. PubMed ID: 35672549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlates of Dapivirine Vaginal Ring Acceptance among Women Participating in an Open Label Extension Trial.
    Mirembe BG; Cabrera MV; van der Straten A; Nakalega R; Cobbing M; Mgodi NM; Palanee-Phillips T; Mayo AJ; Dadabhai S; Mansoor LE; Siva S; Nair G; Chinula L; Akello CA; Nakabiito C; Soto-Torres LE; Baeten JM; Brown ER
    AIDS Behav; 2023 Mar; 27(3):1030-1043. PubMed ID: 36066762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Self-reported removal and expulsion of the dapivirine vaginal ring: qualitative reports from female ring users and their male partners in the Ring Study (IPM 027).
    Milford C; Ramlal H; Mofokeng R; Rambally Greener L; Nel A; Smit J; Malherbe M
    BMC Public Health; 2024 May; 24(1):1458. PubMed ID: 38822304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acceptability of the dapivirine vaginal ring for HIV-1 prevention among women reporting engagement in transactional sex.
    Browne EN; Torjesen K; Mirembe BG; Palanee-Phillips T; Jeenarain N; Chitukuta M; Stoner MCD; Mansoor LE; Reddy K; Tauya TT; Naidoo L; Siva S; Richardson B; Dadabhai S; Seyama L; Soto-Torres L; van der Straten A;
    AIDS Care; 2024 Jan; 36(1):80-86. PubMed ID: 37066990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Men's Sexual Experiences with the Dapivirine Vaginal Ring in Malawi, South Africa, Uganda and Zimbabwe.
    Montgomery ET; Katz AWK; Duby Z; Mansoor LE; Morar NS; Naidoo K; Tsidya M; Chitukuta M; Guma V; Tenza S; Leslie J; Garcia M; Naidoo S
    AIDS Behav; 2021 Jun; 25(6):1890-1900. PubMed ID: 33389318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV-1 acquisition: a secondary analysis from a randomized, placebo-controlled trial.
    Brown ER; Hendrix CW; van der Straten A; Kiweewa FM; Mgodi NM; Palanee-Philips T; Marzinke MA; Bekker LG; Soto-Torres L; Hillier SL; Baeten JM;
    J Int AIDS Soc; 2020 Nov; 23(11):e25634. PubMed ID: 33206462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.